Applied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDA
By Chris Wack
Applied Therapeutics shares were up 11% to $1.40 after the company successfully completed a recent pre-New Drug Application meeting with the U.S. Food and Drug Administration regarding its govorestat Galactosemia program.
The stock hit its 52-week high of $2.18 on May 1, and is down 1% in the past 12 months.
Based on discussions with the FDA, the biopharmaceutical company believes it is aligned with the FDA and plans to submit an NDA for govorestat for the treatment of Galactosemia in the fourth quarter.
Applied Therapeutics said the FDA expressed its support for a potential NDA based on the govorestat data generated to date in Galactosemia, and provided constructive recommendations for successful NDA acceptance and review.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 06, 2023 10:53 ET (14:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying